Close Menu

NEW YORK – Molecular diagnostic startup Summit Biolabs said on Wednesday that it has partnered with the Colorado Center for Personalized Medicine (CCPM) to develop and commercialize saliva-based liquid biopsy tests for head and neck cancer, COVID-19, and other viral diseases.

As part of the agreement, Aurora, Colorado-based Summit Biolabs will integrate CCPM's research biobank, which contains clinical data from more than 8.7 million deidentified patient records, with personalized genomic information to develop the assays.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.